Regenerative medicine is a relatively new field that involves nonoperative biologics that are able to repair tissue damage in one’s body. The journey of R3 Stem Cell began over a decade ago during Dr. Greene’s time at Arizona State’s WP Carey School of Business, he formulated R3 Stem Cell as part of a Marketing Class project. The ‘fake’ company was so well received by his professors, he realized by making the company real it would help thousands of people as the technology improved.
After incorporating the company in 2012, R3 Stem Cell began a slow expansion throughout the USA with an affiliate program. The program incorporated marketing, research, patient/provider education, and top-notch biologics. After five years, Dr. Greene realized the next step was for global expansion. Mexico and Pakistan have been the first countries outside the US for expansion, with four other countries gradually coming to fruition.
No doubt, there have been both good and bad “actors” in this field. Others in the industry have disseminated inaccurate information designed to mislead patients and charge exorbitant fees without value to justify what is being offered. Founded in 2012, R3 Stem Cell has been the distinguisher that offers patients accurate, comprehensive education along with safe and effective clinical therapies that are extremely affordable. The company’s winning business formula has enabled it to continue expansion even during the pandemic.
Alternative Treatments to Avoid Surgery
R3 offers therapies that harness the body’s regenerative capabilities to bring patients hope and options. Hope that surgery can be avoided, and tissue injury can be repaired with the ability to do things normally andpain-free. Existing pain management therapies have been great for suppressing pain by masking discomfort with medications such as cortisone, opiates, or anti-inflammatory medications.These treatments work well for relief, but they don’t actually fix the underlying problem. It’s like placing a Band-Aid over the issue, but the root painful issue remains. R3 Stem Cell is the only US company to have achieved Institutional Review Board Approval for the investigation of regenerative therapies with amniotic and umbilical cord tissue for several condition categories.
regenerate and restore damaged tissue. This allows individuals to reduce pain and cost-effectively increase functional ability with a low-risk profile. The company believes in making a difference in patients’ lives by helping them avoid surgery and remain as active as desired. In addition, R3 desires to contribute substantially to the growing body of research on regenerative medicine by performing IRB Approved Clinical Trials destined for regulatory approvals.
